|
gptkbp:instanceOf
|
gptkb:brand
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:goserelin
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
1987
|
|
gptkbp:ATCCode
|
gptkb:L02AE03
|
|
gptkbp:CASNumber
|
gptkb:65807-02-5
|
|
gptkbp:category
|
hormonal therapy
oncology drug
|
|
gptkbp:chemicalFormula
|
C59H84N18O14
|
|
gptkbp:contraindication
|
pregnancy
hypersensitivity to goserelin
|
|
gptkbp:countryOfOperation
|
gptkb:Australia
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:drugClass
|
gptkb:gonadotropin-releasing_hormone_agonist
|
|
gptkbp:eliminationHalfLife
|
2-4 hours
|
|
gptkbp:form
|
implant
10.8 mg implant
3.6 mg implant
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zoladex
|
|
gptkbp:KEGGID
|
D02368
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:AstraZeneca
|
|
gptkbp:mechanismOfAction
|
suppresses production of sex hormones
|
|
gptkbp:MedlinePlusID
|
a601043
|
|
gptkbp:pregnancyCategory
|
D
X
|
|
gptkbp:PubChem_CID
|
16129731
DB00014
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:RxNorm
|
6177
|
|
gptkbp:sideEffect
|
decreased libido
mood changes
sweating
hot flashes
erectile dysfunction
bone thinning
|
|
gptkbp:synonym
|
gptkb:Zoladex_LA
gptkb:goserelin_implant
|
|
gptkbp:UNII
|
Q150X3729B
|
|
gptkbp:usedFor
|
gptkb:cancer
prostate cancer
assisted reproduction
endometriosis
uterine fibroids
|
|
gptkbp:bfsParent
|
gptkb:AstraZeneca_US
gptkb:Zeneca
|
|
gptkbp:bfsLayer
|
6
|